Skip to main content

32 Result(s)

within Article Remove this filter Haruyasu Murakami Remove this filter Medicine & Public Health Remove this filter Cancer Research Remove this filter

previous disabled Page of 2
and

  1. No Access

    Article

    Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study

    MET exon 14 skip** mutations occur in 3–4% and MET high amplifications occur in < 1% of patients with non-small-cell lung cancer (NSCLC). Crizotinib, a selective ATP-competitive small-molecule inhibitor of c-Me...

    Kaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa… in International Journal of Clinical Oncology (2024)

  2. No Access

    Article

    The efficacy and safety of anamorelin among patients with diabetes

    Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of diabetes on the effic...

    Kenju Ando, Tateaki Naito, Satoshi Hamauchi… in International Journal of Clinical Oncology (2024)

  3. No Access

    Article

    Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing

    Although various companion diagnostic tests of ALK fusion gene-rearrangement are approved, few reports have assessed the concordance of ALK fusion gene-rearrangement in two companion diagnostic tests: next-genera...

    Kazushige Wakuda, Meiko Morita… in International Journal of Clinical Oncology (2024)

  4. No Access

    Article

    Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments

    Trophoblast cell-surface antigen 2 (TROP2) is expressed on the surface of trophoblast cells and many malignant tumor cells. However, data on TROP2 expression in advanced lung cancer are insufficient, and its c...

    Shota Omori, Koji Muramatsu, Takuya Kawata… in Journal of Cancer Research and Clinical On… (2022)

  5. No Access

    Article

    Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients

    To evaluate the relationship between treatment efficacy and exposure of total and unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating...

    Hirotsugu Kenmotsu, Chiyo K. Imamura… in Cancer Chemotherapy and Pharmacology (2022)

  6. No Access

    Article

    Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

    This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC).

    Hideyuki Harada, Shota Omori, Keita Mori… in International Journal of Clinical Oncology (2022)

  7. No Access

    Article

    Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy

    The expression of programmed cell death-ligand 1 (PD-L1) is a biomarker for administering immune check point inhibitors in patients with advanced stage non-small cell lung cancer. Although the consolidation th...

    Nobuaki Mamesaya, Koji Muramatsu… in International Journal of Clinical Oncology (2021)

  8. No Access

    Article

    Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity

    Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dos...

    Takahisa Kawamura, Chiyo K. Imamura… in Cancer Chemotherapy and Pharmacology (2020)

  9. No Access

    Article

    Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

    The expression of programmed death ligand 1 (PD-L1) is considered a predictive biomarker of anti-programmed death 1 (PD-1)/PD-L1 cancer therapies. However, changes in PD-L1 expression of tumor cells during cli...

    Shota Omori, Hirotsugu Kenmotsu, Masato Abe… in International Journal of Clinical Oncology (2018)

  10. No Access

    Article

    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer

    Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival ...

    Hirotsugu Kenmotsu, Yasuhisa Ohde, Kazushige Wakuda… in Cancer Chemotherapy and Pharmacology (2017)

  11. No Access

    Article

    Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer

    Currently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identif...

    Haruki Kobayashi, Shota Omori… in International Journal of Clinical Oncology (2017)

  12. No Access

    Article

    The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum

    This study was to determine the incidence and risk factors of febrile neutropenia in chemotherapy-naïve Japanese patients treated systemically with etoposide plus platinum for lung cancer.

    Takumi Fujiwara, Hirotsugu Kenmotsu, Tateaki Naito… in Cancer Chemotherapy and Pharmacology (2017)

  13. No Access

    Article

    A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors

    MEDI-575 is a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor alpha (PDGFRα). This open-label Phase I study assessed the safety and tolerability of MEDI-575 in...

    Haruyasu Murakami, Masafumi Ikeda, Takuji Okusaka… in Cancer Chemotherapy and Pharmacology (2015)

  14. No Access

    Article

    The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

    It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutatio...

    Ryo Ko, Hirotsugu Kenmotsu, Yasushi Hisamatsu… in International Journal of Clinical Oncology (2015)

  15. No Access

    Article

    Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

    The prognosis of non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is unclear. To assess the prognosis of NSCLC patients with ILD treated with platinum-based chemotherapy, we ret...

    Hirotsugu Kenmotsu, Tateaki Naito, Keita Mori… in Cancer Chemotherapy and Pharmacology (2015)

  16. No Access

    Article

    Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens

    It is often difficult to diagnose large cell neuroendocrine carcinomas (LCNEC) of the lung using small biopsy specimens. Some recent studies attempted to diagnose LCNEC using biopsy specimens; in 2011, the Int...

    Takaaki Tokito, Hirotsugu Kenmotsu… in International Journal of Clinical Oncology (2014)

  17. No Access

    Article

    Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases

    Skeletal-related events (SREs) negatively affect the quality of life of patients with cancer. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone metastasis in animal...

    Takaaki Tokito, Takehito Shukuya, Hiroaki Akamatsu… in Cancer Chemotherapy and Pharmacology (2013)

  18. No Access

    Article

    The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

    The aim of this study is to evaluate whether class III β-tubulin (TUBB3) expression could predict progression-free survival or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated w...

    Kyoichi Kaira, Toshiaki Takahashi… in International Journal of Clinical Oncology (2013)

  19. No Access

    Article

    Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

    A phase I dose-escalation study was performed to investigate the safety and pharmacokinetics of the combination of S-1 and gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.

    Hidemi Kiyota, Isamu Okamoto, Masayuki Takeda… in Cancer Chemotherapy and Pharmacology (2013)

  20. Article

    Open Access

    Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

    This study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors.

    Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto… in Cancer Chemotherapy and Pharmacology (2012)

    Download PDF (228 KB) View Article
previous disabled Page of 2